Literature DB >> 8595548

The current role of percutaneous biopsy in the evaluation of renal masses.

B R Herts1, M E Baker.   

Abstract

Percutaneous biopsy of intraabdominal masses is a safe and accurate means of obtaining a tissue diagnosis without surgical exploration. It is often sufficient to determine treatment plans and in many instances, obviates the need for surgery. Percutaneous biopsy of renal masses has traditionally had a limited role in the United States. However, with a recent increase in the detection of small renal masses because of the widespread use of abdominal computed tomography (CT), there is an increasing role for percutaneous biopsy in the management of renal masses. Percutaneous biopsy of renal masses is indicated to differentiate between a primary renal cell carcinoma and metastatic disease in patients with a known extrarenal primary. Percutaneous biopsy is also indicated to establish a diagnosis of renal lymphoma and abscess. Complications of percutaneous biopsy include bleeding, pneumothorax, and tumor seeding along the needle tract; fortunately, these complications are uncommon. We will review the indications, techniques, complications, sensitivity, and accuracy of CT and ultrasound-guided biopsy of renal masses. Urologists and radiologists should both be familiar with the indications and contraindications of percutaneous biopsy to insure the appropriate management of renal masses.

Entities:  

Mesh:

Year:  1995        PMID: 8595548

Source DB:  PubMed          Journal:  Semin Urol Oncol        ISSN: 1081-0943


  32 in total

1.  Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses.

Authors:  Aliaksei Chyhrai; Jimsgene Sanjmyatav; Mieczyslaw Gajda; Olaf Reichelt; Heiko Wunderlich; Thomas Steiner; Enis Tanović; Kerstin Junker
Journal:  World J Urol       Date:  2010-06       Impact factor: 4.226

Review 2.  Role of percutaneous needle biopsy for renal masses.

Authors:  Elaine M Caoili; Matthew S Davenport
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

3.  Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma.

Authors:  F Cornelis; E Tricaud; A S Lasserre; F Petitpierre; J C Bernhard; Y Le Bras; M Yacoub; M Bouzgarrou; A Ravaud; N Grenier
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

4.  Ablative therapies for renal tumors.

Authors:  Rajan Ramanathan; Raymond J Leveillee
Journal:  Ther Adv Urol       Date:  2010-04

5.  Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours.

Authors:  F Cornelis; E Tricaud; A S Lasserre; F Petitpierre; J C Bernhard; Y Le Bras; M Yacoub; M Bouzgarrou; A Ravaud; N Grenier
Journal:  Eur Radiol       Date:  2014-02-21       Impact factor: 5.315

6.  Renal cell carcinoma seeding of a percutaneous biopsy tract.

Authors:  Jeffrey K Mullins; Ronald Rodriguez
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

7.  Prevention of tumour cell dissemination in diagnostic needle procedures.

Authors:  H Wiksell; K-U Schässburger; M Janicijevic; K Leifland; L Löfgren; S Rotstein; P-O Sandberg; C Wadström; G Auer
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

8.  Extensive renal infarction following percutaneous biopsy of a small renal mass: A case report.

Authors:  Samuel Abourbih; Saad Aldousari; Fadi Brimo; Atilla Omeroglu; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

9.  Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Authors:  Chaitanya R Divgi; Robert G Uzzo; Constantine Gatsonis; Roman Bartz; Silke Treutner; Jian Qin Yu; David Chen; Jorge A Carrasquillo; Steven Larson; Paul Bevan; Paul Russo
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

Review 10.  Biopsy of renal masses: when and why.

Authors:  V Anik Sahni; Stuart G Silverman
Journal:  Cancer Imaging       Date:  2009-07-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.